Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986451 | 0.84 | ALDH1A1 (0.44) | ALDH1A1IDO1KMT2AKDM4EGAA | |
| SCHEMBL29472228 | 0.83 | IDO1 (0.38) | ALDH1A1TSHRSMN1; SMN2IDO1KMT2A | |
| SCHEMBL17336426 | 0.81 | KDM4E (0.45) | ALDH1A1KMT2AKDM4EMEN1HTT | |
| SCHEMBL18130476 | 0.81 | ALDH1A1 (0.49) | ALDH1A1TSHRSMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL29472242 | 0.80 | KCNQ4 (0.42) | KDM4EGAA | |
| SCHEMBL5447593 | 0.80 | PPIB (0.50) | ALDH1A1IDO1KMT2AMEN1GAA | |
| SCHEMBL17336386 | 0.79 | PPIB (0.55) | ALDH1A1SMN1; SMN2KMT2ALMNAKDM4E | |
| SCHEMBL23723732 | 0.78 | ALDH1A1 (0.48) | ALDH1A1TSHRSMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL17336383 | 0.78 | MTNR1A (0.48) | — | |
| SCHEMBL4704775 | 0.77 | CYP17A1 (0.43) | KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| EP-3154634-B1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | UNIV LILLE (FR) | 2021-02-24 | — | — | EP | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10323016-B2 | Imidazol- or 1,2,4-triazol-derivatives and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-06-18 | — | — | US | disclosed |
| EP-3280707-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2018-02-14 | — | — | EP | disclosed |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
| CN-107428754-A | Two ring Quinazol derivatives | 豪夫迈·罗氏有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20170190687-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | Université de Lille (FR) | 2017-07-06 | — | — | US | disclosed |
| EP-3154634-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | Université de Lille 2 Droit et Santé (FR) | 2017-04-19 | — | — | EP | disclosed |
| WO-2016162390-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-13 | — | — | WO | disclosed |
| WO-2015189330-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | ALDH1A1 975/4885TSHR 1237/4885SMN1; SMN2 2930/4885 |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | ALDH1A1 975/4885TSHR 1237/4885SMN1; SMN2 2930/4885 |
| US-20170190687-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | CYP3A43, CYP51A1, CYP3A7 | ALDH1A1 436/4885TSHR 1732/4885SMN1; SMN2 2642/4885 |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | BRD4, BICRA, NDUFC2 | ALDH1A1 975/4885TSHR 1237/4885SMN1; SMN2 2930/4885 |
| US-10323016-B2 | Imidazol- or 1,2,4-triazol-derivatives and their use | CYP3A43, CYP51A1, CYP3A7 | ALDH1A1 436/4885TSHR 1732/4885SMN1; SMN2 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.